- Report
- October 2025
- 280 Pages
Global
From €5233EUR$5,850USD£4,603GBP
- Report
- March 2025
- 200 Pages
Global
From €4016EUR$4,490USD£3,533GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1073EUR$1,200USD£944GBP
€1342EUR$1,500USD£1,180GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1073EUR$1,200USD£944GBP
€1342EUR$1,500USD£1,180GBP
- Report
- January 2025
- 175 Pages
Global
From €4016EUR$4,490USD£3,533GBP
- Report
- June 2024
- 200 Pages
Global
From €5689EUR$6,360USD£5,004GBP
€7111EUR$7,950USD£6,255GBP
- Report
- June 2024
- 200 Pages
Global
From €5689EUR$6,360USD£5,004GBP
€7111EUR$7,950USD£6,255GBP
- Report
- July 2024
- 114 Pages
Global
From €4249EUR$4,750USD£3,737GBP
- Report
- October 2024
- 70 Pages
Global
From €3126EUR$3,495USD£2,750GBP
The Neurofibromatosis Drug market is a subset of the Central Nervous System Drugs market. It is composed of drugs used to treat neurofibromatosis, a genetic disorder that causes tumors to grow on nerve tissue. These drugs are used to reduce the size of tumors, reduce pain, and improve quality of life. Commonly used drugs include anticonvulsants, antipsychotics, and corticosteroids.
The Neurofibromatosis Drug market is highly competitive, with many companies offering similar products. Some of the major players in the market include Novartis, Pfizer, Merck, and Roche. Other companies include Sanofi, GlaxoSmithKline, and AstraZeneca. Show Less Read more
